CompletedPhase 3NCT03025789
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Victor Kande Betu Kumeso, MDMinistry of Health, Kinshasa, The Democratic Republic of the Congo
- Intervention
- Fexinidazole(drug)
- Enrollment
- 174 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2016 – 2021
Study locations (8)
- Dipumba Hospital, Mbuji-Mayi, Kasaï Oriental Province, Democratic Republic of the Congo
- Bagata Hospital, Bagata, Kwilu, Democratic Republic of the Congo
- Bandundu Hospital, Bandundu Province, Kwilu, Democratic Republic of the Congo
- Masi Manimba Hospital, Masi-Manimba, Kwilu, Democratic Republic of the Congo
- Nkara Secondary Hospital, Nkara, Kwilu, Democratic Republic of the Congo
- Mushie Hospital, Mushie, Maï Ndombe Province, Democratic Republic of the Congo
- Roi Baudouin Hospital, Kinshasa, Democratic Republic of the Congo
- Dubreka Hospital, Dubréka, Guinea
Collaborators
Sanofi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03025789 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)